INNOVATION1 BIOTECH INC. Innovation1 Biotech Inc. announced the appointment of the Company's Chief Science Officer, Andrew L. Salzman, M.D., to its Board of Directors. Dr. Salzman is a physician, scientist, inventor, and biomedical entrepreneur with more than 30 years' experience in biomedical drug discovery and development. He has authored 175 peer-reviewed scientific publications and holds 60 patents in the fields of medicine, pharmacology, organic chemistry, and medical devices.
Dr. Salzman has received continuous National Institutes of Health (NIH) funding since 1993, authoring 75 federal grants and receiving $160 million in federal grant and contract funding. He earned his Doctor of Medicine degree from Harvard Medical School after completing undergraduate training at Yale College. Dr. Salzman completed his pediatric internship and residency at Columbia University, and post-doctoral fellowships in pediatric critical care, neonatal critical care, immunology, mucosal physiology, and pediatric infectious disease at the Weizmann Institute of Science, Boston Children's Hospital Medical Center, the Massachusetts General Hospital, and Beth Israel Hospital Medical Center.
Dr. Salzman is an internationally recognized authority on free radical and oxidant mediated tissue injury. He founded and led the Division of Critical Care Medicine at Cincinnati Children's Hospital Medical Center. For the last 20 years he has founded and led biotechnology companies that have invented and developed novel pharmaceutical therapeutics.
Among these, he has invented and developed the first PARP inhibitor (INO-1001, licensed to Genentech), the first adenosine 1 receptor agonist to enter clinical trials (trabadenoson, resulting in a NASDAQ IPO), and the first recombinant cystathionine beta synthase enzyme for classical homozygous homocystinuria (Pegtibatinase sold to Travere Therapeutics).
